Oncogenuity
Private Company
Total funding raised: $31.2M
Overview
Oncogenuity is a preclinical-stage biotech leveraging a proprietary oligonucleotide platform to develop gene-silencing therapies that act at the DNA level. Its lead asset targets the historically 'undruggable' KRAS G12D mutation prevalent in pancreatic, colorectal, and other cancers, with a significant estimated market opportunity. The company, founded in 2018 and based in Cambridge, USA, is also exploring the platform's utility against COVID-19 and various genetic disorders, positioning it in the high-potential but high-risk RNA and gene therapy sector.
Technology Platform
Proprietary ONCOlogue platform using Peptide Nucleic Acids (PNAs) to silence disease-causing genes at the DNA level by invading mutant DNA strands to halt transcription.
Funding History
2Opportunities
Risk Factors
Competitive Landscape
In KRAS inhibition, Oncogenuity competes with companies like Amgen, Mirati, and others who have approved or late-stage G12C inhibitors, and a growing field targeting G12D. In gene silencing, it faces broad competition from siRNA and antisense oligonucleotide companies. Its DNA-targeting approach is a differentiating but less validated strategy.